[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3494962T3 - Flydende inhalationsformulering omfattende RPL554 - Google Patents

Flydende inhalationsformulering omfattende RPL554 Download PDF

Info

Publication number
DK3494962T3
DK3494962T3 DK19152629.2T DK19152629T DK3494962T3 DK 3494962 T3 DK3494962 T3 DK 3494962T3 DK 19152629 T DK19152629 T DK 19152629T DK 3494962 T3 DK3494962 T3 DK 3494962T3
Authority
DK
Denmark
Prior art keywords
rpl554
inhalation formulation
liquid inhalation
liquid
formulation
Prior art date
Application number
DK19152629.2T
Other languages
English (en)
Inventor
Peter Lionel Spargo
Edward James French
Phillip A Haywood
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1416274.7A external-priority patent/GB201416274D0/en
Priority claimed from GBGB1504662.6A external-priority patent/GB201504662D0/en
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Application granted granted Critical
Publication of DK3494962T3 publication Critical patent/DK3494962T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK19152629.2T 2014-09-15 2015-09-15 Flydende inhalationsformulering omfattende RPL554 DK3494962T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416274.7A GB201416274D0 (en) 2014-09-15 2014-09-15 Formulation
GBGB1504662.6A GB201504662D0 (en) 2015-03-19 2015-03-19 Formulation
EP17207623.4A EP3332767B1 (en) 2014-09-15 2015-09-15 Liquid inhalation formulation comprising rpl554

Publications (1)

Publication Number Publication Date
DK3494962T3 true DK3494962T3 (da) 2021-06-21

Family

ID=54196992

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17207623.4T DK3332767T3 (da) 2014-09-15 2015-09-15 Flydende inhalationsformulering, der omfatter RPL554
DK19152629.2T DK3494962T3 (da) 2014-09-15 2015-09-15 Flydende inhalationsformulering omfattende RPL554
DK15770593.0T DK3193835T3 (da) 2014-09-15 2015-09-15 Flydende inhalationsformulering, der omfatter RPL554

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17207623.4T DK3332767T3 (da) 2014-09-15 2015-09-15 Flydende inhalationsformulering, der omfatter RPL554

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15770593.0T DK3193835T3 (da) 2014-09-15 2015-09-15 Flydende inhalationsformulering, der omfatter RPL554

Country Status (26)

Country Link
US (2) US9956171B2 (da)
EP (3) EP3193835B1 (da)
JP (2) JP6860477B2 (da)
KR (1) KR102379309B1 (da)
CN (3) CN111249260B (da)
AU (3) AU2015316592B2 (da)
CA (1) CA2959943C (da)
CY (3) CY1120264T1 (da)
DK (3) DK3332767T3 (da)
ES (3) ES2875584T3 (da)
HK (1) HK1249415B (da)
HR (3) HRP20180833T1 (da)
HU (3) HUE055527T2 (da)
IL (1) IL250895B (da)
LT (3) LT3494962T (da)
MX (1) MX2017003102A (da)
MY (1) MY196072A (da)
NO (1) NO3193835T3 (da)
PH (1) PH12017500479B1 (da)
PL (3) PL3332767T3 (da)
PT (3) PT3332767T (da)
RS (3) RS62252B1 (da)
RU (1) RU2699995C2 (da)
SG (1) SG11201701854WA (da)
SI (3) SI3332767T1 (da)
WO (1) WO2016042313A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173551A1 (en) 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
SG11201701854WA (en) * 2014-09-15 2017-04-27 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
US10947272B2 (en) 2015-07-24 2021-03-16 Hoffmann-La Roche Inc. BACE1 inhibitor peptides
GB201613054D0 (en) 2016-07-28 2016-09-14 Verona Pharma Plc New compound and process
GB2578093B (en) 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
JP6994061B2 (ja) * 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
GB201911517D0 (en) 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
CA3167378A1 (en) 2020-01-15 2021-07-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound
GB202002786D0 (en) 2020-02-27 2020-04-15 Verona Pharma Plc Liquid pharmaceutical composition
GB202202297D0 (en) * 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2024033627A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc Liquid pharmaceutical composition
WO2024033626A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Plc Ensifentrine (rpl-554) for decreasing the frequency and/or severity of copd exacerbations
TW202421154A (zh) * 2022-10-28 2024-06-01 大陸商江蘇恆瑞醫藥股份有限公司 一種包含異喹啉酮類化合物的醫藥組成物及其製備方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
DE69804998T2 (de) 1997-10-09 2002-12-12 Schering Corp., Kenilworth Mometasonfuroat-suspensionen zum zerstäuben
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
DK1165558T3 (da) 1999-03-31 2004-02-09 Vernalis Ltd Pyrimido[6,1-a]isoquinolin-4-on-derivater
US6630169B1 (en) * 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US7579505B2 (en) 2004-12-17 2009-08-25 Cipla Limited Crystalline levosalbutamol sulphate and polymorphic forms thereof
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2011161018A1 (en) 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Alkaloid aminoester derivatives and medicinal compositions thereof
EP2603509B1 (en) * 2010-08-09 2014-06-18 Verona Pharma PLC Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
AU2012267938B2 (en) * 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
EP2647627A1 (en) * 2012-04-02 2013-10-09 Almirall, S.A. Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one.
WO2014037727A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Carcainium salts
DK2968312T3 (da) * 2013-03-15 2018-05-07 Verona Pharma Plc Lægemiddelkombination
WO2015173551A1 (en) 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
SG11201701854WA (en) * 2014-09-15 2017-04-27 Verona Pharma Plc Liquid inhalation formulation comprising rpl554
GB201502260D0 (en) * 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound

Also Published As

Publication number Publication date
US10945950B2 (en) 2021-03-16
AU2018286571A1 (en) 2019-01-24
RU2017108432A3 (da) 2019-04-01
EP3494962A1 (en) 2019-06-12
MY196072A (en) 2023-03-13
CN110051627A (zh) 2019-07-26
JP2017528479A (ja) 2017-09-28
KR20170054406A (ko) 2017-05-17
EP3332767B1 (en) 2019-03-20
NO3193835T3 (da) 2018-08-04
KR102379309B1 (ko) 2022-03-28
HRP20191122T1 (hr) 2019-09-20
LT3193835T (lt) 2018-06-11
CA2959943A1 (en) 2016-03-24
SG11201701854WA (en) 2017-04-27
JP6860477B2 (ja) 2021-04-14
HUE055527T2 (hu) 2021-12-28
PL3494962T3 (pl) 2021-12-06
SI3494962T1 (sl) 2021-09-30
ES2875584T3 (es) 2021-11-10
EP3332767A1 (en) 2018-06-13
NZ767295A (en) 2024-01-26
HK1249415B (zh) 2019-11-22
IL250895B (en) 2019-08-29
PH12017500479A1 (en) 2017-07-31
CN111249260A (zh) 2020-06-09
CA2959943C (en) 2022-08-16
SI3193835T1 (en) 2018-06-29
NZ767296A (en) 2024-01-26
PL3193835T3 (pl) 2018-07-31
RU2017108432A (ru) 2018-10-17
CN106794157A (zh) 2017-05-31
PL3332767T3 (pl) 2019-10-31
EP3193835B1 (en) 2018-03-07
US20180369139A1 (en) 2018-12-27
JP2019069978A (ja) 2019-05-09
PT3193835T (pt) 2018-03-27
ES2730810T3 (es) 2019-11-12
MX2017003102A (es) 2017-06-14
AU2020203081B2 (en) 2021-08-05
AU2018286571B2 (en) 2020-04-02
CY1121698T1 (el) 2020-07-31
SI3332767T1 (sl) 2019-07-31
NZ729796A (en) 2024-01-26
EP3193835A1 (en) 2017-07-26
CN111249260B (zh) 2023-01-10
HRP20211035T1 (hr) 2021-09-17
LT3332767T (lt) 2019-06-25
JP6795574B2 (ja) 2020-12-02
ES2670025T3 (es) 2018-05-29
HRP20180833T1 (hr) 2018-06-29
PT3494962T (pt) 2021-06-22
IL250895A0 (en) 2017-04-30
CY1120264T1 (el) 2019-07-10
AU2015316592B2 (en) 2020-04-02
RS58897B1 (sr) 2019-08-30
RU2699995C2 (ru) 2019-09-12
RS57227B1 (sr) 2018-07-31
HUE045303T2 (hu) 2019-12-30
PH12017500479B1 (en) 2017-07-31
US9956171B2 (en) 2018-05-01
CY1124546T1 (el) 2022-07-22
LT3494962T (lt) 2021-07-26
PT3332767T (pt) 2019-06-27
EP3494962B1 (en) 2021-05-26
CN106794157B (zh) 2021-03-09
AU2015316592A1 (en) 2017-03-23
HUE038433T2 (hu) 2018-10-29
US20170239178A1 (en) 2017-08-24
RS62252B1 (sr) 2021-09-30
WO2016042313A1 (en) 2016-03-24
BR112017005050A2 (pt) 2018-01-23
AU2020203081A1 (en) 2020-05-28
DK3332767T3 (da) 2019-06-24
DK3193835T3 (da) 2018-05-07

Similar Documents

Publication Publication Date Title
HK1249415B (zh) 包含rpl554的液體吸入製劑
DK3236749T3 (da) Flydende tribenuron-holdige herbicidsammensætninger
BR112016026879A2 (pt) Composição farmacêutica líquida
DK3145488T3 (da) Flydende farmaceutiske forbindelse
DK3193840T3 (da) Arimoclomol-formulering
FI20145117A (fi) Stabiloitu liima-aineformulaatio
DK3102275T3 (da) Nasal dilatator
FR3021528B1 (fr) Formulation cosmetique
FI20145118A (fi) Stabiloitu liima-aineformulaatio
DK3200762T3 (da) Inhalationsanordning
DK3148513T3 (da) Ceritinib-formulering
FI20145982A (fi) Potilasalusta
DK3193856T3 (da) Formulering
DK3441063T3 (da) Flydende thioureylensammensætninger
UA31168S (uk) Інгалятор
UA30864S (uk) Інгалятор
UA30748S (uk) Інгалятор
TH1501007686A (th) สูตรตำรับของเหลวเสถียร
UA28875S (uk) Шприц
UA28872S (uk) Шприц
TH1501006804A (th) องค์ประกอบของเหลวไอออนิก
ES1112405Y (es) Mosquetón
UA30163S (uk) Спринцівка
UA30164S (uk) Спринцівка
TH1501007638A (th) สารรักษาความชุ่มชื้น